Bromocriptine Mesilate + Placebos

Phase 1/2Completed

3 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Familial Alzheimer Disease (FAD)

Conditions

Familial Alzheimer Disease (FAD), PSEN1 Mutation

Trial Timeline

Jun 5, 2020 → Nov 24, 2021

NCT ID

NCT04413344

About Bromocriptine Mesilate + Placebos

Bromocriptine Mesilate + Placebos is a phase 1/2 stage product being developed by Towa Pharmaceutical for Familial Alzheimer Disease (FAD). The current trial status is completed. This product is registered under clinical trial identifier NCT04413344. Target conditions include Familial Alzheimer Disease (FAD), PSEN1 Mutation.

What happened to similar drugs?

5 of 20 similar drugs in Familial Alzheimer Disease (FAD) were approved

Approved (5) Terminated (3) Active (14)

✅EvolocumabAmgenApproved

✅evolocumabAmgenApproved

✅AnakinraSwedish Orphan BiovitrumApproved

✅Colesevelam hydrochloride film-coated tablets + PlaceboSanofiApproved

✅PraluentSanofiApproved

🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3

🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04413344	Phase 1/2	Completed	Jun 5, 2020	Nov 24, 2021	Familial Alzheimer Disease (FAD)

Competing Products

20 competing products in Familial Alzheimer Disease (FAD)

See all competitors

Product	Company	Stage	Hype Score
SHR-1209	Jiangsu Hengrui Medicine	Phase 2	31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo	Jiangsu Hengrui Medicine	Phase 3	40
Rosuvastatin 20mg + Placebo	AstraZeneca	Phase 3	40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin 20mg	AstraZeneca	Phase 3	40
AZD0780 + Placebo	AstraZeneca	Phase 3	44
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	40
Statins and Ezetimibe	Merck	Pre-clinical	22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo	Merck	Phase 3	32
MK-0524A + MK-0524A	Merck	Phase 1	21
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	45
Inclisiran + Placebo	Novartis	Phase 3	40
DFV890	Novartis	Phase 2	35
Canakinumab	Novartis	Phase 2	35
Inclisiran Sodium for injection + Placebo + Placebos	Novartis	Phase 3	40
LCQ908 + Placebo	Novartis	Phase 3	40
Inclisiran	Novartis	Phase 3	44
Inclisiran + Placebo	Novartis	Phase 3	40
Fluvastatin	Novartis	Phase 3	40